{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:35:35Z","timestamp":1793068535171,"version":"4.5.0"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.2967\/jnumed.121.263056","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T22:35:15Z","timestamp":1645742115000},"page":"1503-1508","source":"Crossref","is-referenced-by-count":25,"title":["Safety of Peptide Receptor Radionuclide Therapy with <sup>177<\/sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease"],"prefix":"10.2967","volume":"63","author":[{"given":"Shahad","family":"Alsadik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luohai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalvinder","family":"Mandair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"2022100315301344000_63.10.1503.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2022100315301344000_63.10.1503.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2022100315301344000_63.10.1503.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2677-3"},{"key":"2022100315301344000_63.10.1503.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"2022100315301344000_63.10.1503.5","unstructured":"Annex I: summary of product characteristics. EMA website. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf. Accessed July 7, 2022."},{"key":"2022100315301344000_63.10.1503.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0457-7"},{"key":"2022100315301344000_63.10.1503.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"2022100315301344000_63.10.1503.8","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med."},{"key":"2022100315301344000_63.10.1503.9","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050476"},{"key":"2022100315301344000_63.10.1503.10","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med."},{"key":"2022100315301344000_63.10.1503.11","unstructured":"Annex I: summary of product characteristics. European Commission website. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170926138665\/anx_138665_en.pdf. Accessed July 7, 2022."},{"key":"2022100315301344000_63.10.1503.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3001-1"},{"key":"2022100315301344000_63.10.1503.13","unstructured":"CKD stages. UK Kidney Association website. https:\/\/renal.org\/health-professionals\/information-resources\/uk-eckd-guide\/ckd-stages. Accessed July 7, 2022."},{"key":"2022100315301344000_63.10.1503.14","unstructured":"EORTC QLQ \u2013 GI.NET21. EORTC website. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/08\/Specimen-GI.NET21-English.pdf. Published 2004. Accessed July 7, 2022."},{"key":"2022100315301344000_63.10.1503.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2022100315301344000_63.10.1503.16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. NIH website. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Published November 27, 2017. Accessed July 7, 2022."},{"key":"2022100315301344000_63.10.1503.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.125336"},{"key":"2022100315301344000_63.10.1503.18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2016.04.006","article-title":"Renal function assessment during peptide receptor radionuclide therapy","volume":"46","author":"Erbas","year":"2016","journal-title":"Semin Nucl Med."},{"key":"2022100315301344000_63.10.1503.19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants","volume":"111","author":"Fr\u00f6ss-Baron","year":"2021","journal-title":"Neuroendocrinology."},{"key":"2022100315301344000_63.10.1503.20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022100315301344000_63.10.1503.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2022100315301344000_63.10.1503.22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022100315301344000_63.10.1503.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1985.tb07117.x"},{"key":"2022100315301344000_63.10.1503.24","first-page":"419","article-title":"Ageing and the glomerular filtration rate: truths and consequences","volume":"120","author":"Glassock","year":"2009","journal-title":"Trans Am Clin Climatol Assoc."},{"key":"2022100315301344000_63.10.1503.25","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundl\u00f6v","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022100315301344000_63.10.1503.26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022100315301344000_63.10.1503.27","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol."},{"key":"2022100315301344000_63.10.1503.28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00259-017-3816-z","article-title":"Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30","volume":"45","author":"Marinova","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:35:54Z","timestamp":1664836554000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,3]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.2967\/jnumed.121.263056"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263056","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}